AI assistant
ADHERIUM LIMITED — Board/Management Information 2017
Feb 22, 2017
64305_rns_2017-02-22_f1ec74a8-2c1c-4704-8d01-b4687d1bc93f.pdf
Board/Management Information
Open in viewerOpens in your device viewer
Announcement
==> picture [136 x 38] intentionally omitted <==
ADHERIUM EXPANDS ITS INTERNATIONAL PRESENCE ANNOUNCES SENIOR APPOINTMENT TO LEAD MARKET EXPANSION FOR ‘REST OF WORLD’
23 February 2017: Adherium Limited (ASX : ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, today announced the appointment of a new Vice President of Business Development for its key markets outside of North America and Europe.
Erin Wansbrough will lead Adherium’s partnering and market expansion for the ‘Rest of World’ territories, including Asia Pacific and the Middle East where Adherium already has approvals to market its Smartinhaler[TM] products in China, Australia and New Zealand. Erin will be operating out of the Company’s existing Asia Pacific base in Auckland, New Zealand.
Ms Wansbrough joins Adherium after a successful career over the last 16 years that spans multiple industries including pharmaceuticals, healthcare, biotechnology, and ICT across both private and public sectors. As a senior professional, Erin has a strong track record with innovative, high-growth companies.
Erin began her career with Life Technologies in New Zealand in Product and Sales Management. She then went on to work for AstraZeneca and GSK in a Sales Management capacity before joining Genesis Research & Development Corporation as Business Development Manager.
Erin is currently a Director of the New Zealand Technology Industry Association (NZTech) and joins Adherium from Callaghan Innovation where she was responsible for building the Business Innovation Group.
Prior to this, Erin spent a period of time in Australia as Business Development Manager with IMBcom, a private company dedicated to the commercialisation of research from one of the leading biotechnology research organisations in Australia, The University of Queensland.
Garth Sutherland, Group CEO of Adherium said:
“I am delighted to welcome Erin to Adherium’s growing global Business Development team. This is a key milestone for us as we continue to build our commercial capabilities to attract and service new customers. Erin has a proven track record of executing commercial partnerships and business development management."
Erin Wansbrough added:
“ It’s been exciting to watch the progress of the company over the last few years and it will be a privilege to join the team to help build Adherium’s future. Fulfilling the promise of empowering people with chronic conditions to live the life they want.”
ABOUT ADHERIUM
Adherium (ASX:ADR) is an Australian Securities Exchange listed company which develops, manufactures and supplies digital health technologies which address sub-optimal medication use and improve health outcomes in chronic disease.
Adherium operates globally from bases in the USA, Europe and Australasia.
Adherium is a provider of digital health solutions to patients, pharmaceutical companies, healthcare providers and contract research organizations. The Company’s proprietary Smartinhaler™ platform has been independently proven to improve medication adherence and health outcomes for patients with chronic respiratory disease. Adherium has the broadest range of "smart" medication sensors for respiratory medications globally.
The Smartinhaler™ platform has so far been used in more than 65 projects (clinical, device validation or other) and has been referenced in 56 peer reviewed journal articles. Clinical outcomes data has proven that the Smartinhaler™ platform can improve adherence by up to 59% in adults and 180% in children and reduce severe episodes by 60% in adults, leading to improved quality-of-life and demonstrating a substantial gain over current best practice treatment. The Company has received FDA 510(k) notifications for clearance to market and CE Marks for its devices and software, which allows it to sell these devices into international markets.
www.adherium.com www.smartinhaler.com
Enquiries:
| At Adherium:Media enquiries: | At Adherium:Media enquiries: | At Adherium:Media enquiries: | At Adherium:Media enquiries: | At Adherium:Media enquiries: | At Adherium:Media enquiries: | ||||
|---|---|---|---|---|---|---|---|---|---|
| Investor RelationsJulia ChambersHead of Corporate DevelopmentM: +64 27 807 8153E:[email protected]Australia and New ZealandRudi MichelsonMonsoon CommunicationsD: +61 3 9620 3333E:[email protected]Rest of WorldErin WansbroughVice PresidentBusiness DevelopmentRest of WorldM: +64 21 766 083E:[email protected] | |||||||||
| North AmericaJames HattersleySenior Vice PresidentBusiness DevelopmentNorth AmericaM: +1 610 955 5886E:[email protected]North AmericaErich SandovalLazar PartnersD: +1 213-908-6226E:[email protected] | |||||||||
| EScSeBEME: | uropeott Flemingnior Vice Presideusiness Developmurope: +31 646 876 98 | ntESIn | uropeue Charles/Rozistinctif Partners | Morris | |||||
| ent9DE | : +44 20 7457 20:adherium@inst | 20inctif.com | |||||||
| scottf@adherium | .com | ||||||||